Synmosa Biopharma Corporation (TPEX:4114)

Synmosa Biopharma Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,186	918.56	1,088	868.17	638.35
Short-Term Investments	120.31	520	310	115	100
Trading Asset Securities	575.94	211.45	20.1	5.26	7.01
Cash & Short-Term Investments	1,882	1,650	1,418	988.43	745.35
Cash Growth	14.08%	16.38%	43.43%	32.61%	30.74%
Accounts Receivable	1,252	1,155	1,125	799.64	702.53
Other Receivables	57.88	48.43	20.86	10.47	16.31
Receivables	1,310	1,203	1,146	810.11	718.84
Inventory	1,787	1,651	1,384	1,214	1,239
Prepaid Expenses	34.54	28.1	-	51.11	47.23
Other Current Assets	5.31	7	60.84	35.05	231.46
Total Current Assets	5,019	4,539	4,008	3,099	2,982
Property, Plant & Equipment	5,589	5,557	5,638	5,662	5,788
Long-Term Investments	336.48	222.87	223.01	303.48	271.52
Goodwill	62.29	62.29	71.08	7.27	13.27
Other Intangible Assets	449.22	496.56	496.8	494.03	536.69
Long-Term Deferred Tax Assets	363.27	330.56	331.78	329.28	311.7
Other Long-Term Assets	484.54	519.9	433.53	421.53	473.71
Total Assets	12,304	11,729	11,203	10,317	10,377
Accounts Payable	471.02	427.54	446.16	249.58	184.26
Accrued Expenses	443.36	381.68	368.47	264.64	260.62
Short-Term Debt	674.89	661.22	584.08	763.77	630.76
Current Portion of Long-Term Debt	72.33	289.39	584.42	413.9	256.53
Current Portion of Leases	22.94	23.3	16.7	6.74	6.83
Current Income Taxes Payable	142.57	118.29	95.54	53.18	54.61
Current Unearned Revenue	163.72	172.29	173.43	126.87	129.31
Other Current Liabilities	83.76	44.71	53.91	10.21	36.74
Total Current Liabilities	2,075	2,118	2,323	1,889	1,560
Long-Term Debt	1,729	1,400	2,122	2,272	2,804
Long-Term Leases	49.86	58.66	48.42	6.76	3.84
Long-Term Unearned Revenue	5.53	2.35	-	-	-
Long-Term Deferred Tax Liabilities	37.42	35.45	34.52	34.2	35.11
Other Long-Term Liabilities	1.26	0.53	12.62	0.89	0.86
Total Liabilities	3,905	3,628	4,554	4,221	4,423
Common Stock	4,293	4,014	3,437	3,131	2,808
Additional Paid-In Capital	2,082	2,195	1,425	1,426	1,403
Retained Earnings	1,096	1,092	1,005	613.43	713.49
Treasury Stock	-205.68	-486.96	-486.96	-402.62	-350.87
Comprehensive Income & Other	-55.82	-104.78	-68.18	-63.04	-73.45
Total Common Equity	7,210	6,710	5,312	4,706	4,500
Minority Interest	1,189	1,391	1,337	1,390	1,455
Shareholders' Equity	8,399	8,101	6,649	6,095	5,955
Total Liabilities & Equity	12,304	11,729	11,203	10,317	10,377
Total Debt	2,549	2,433	3,355	3,463	3,702
Net Cash (Debt)	-666.47	-782.59	-1,937	-2,474	-2,956
Net Cash Per Share	-1.58	-1.92	-4.94	-6.26	-7.65
Filing Date Shares Outstanding	420.25	420.25	390.19	393.6	396.58
Total Common Shares Outstanding	420.25	420.25	390.19	393.6	396.58
Working Capital	2,945	2,421	1,686	1,210	1,423
Book Value Per Share	17.16	15.97	13.61	11.95	11.35
Tangible Book Value	6,699	6,151	4,744	4,204	3,950
Tangible Book Value Per Share	15.94	14.64	12.16	10.68	9.96
Land	3,528	3,528	3,558	3,558	3,567
Buildings	1,587	1,567	1,558	1,542	1,561
Machinery	2,050	1,893	1,790	1,696	1,728
Construction In Progress	89.55	19.08	9.74	62.51	47.32
Leasehold Improvements	83.19	80.49	78.96	22.62	19.93

Source: S&P Global Market Intelligence. Standard template. Financial Sources.